A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
← catalyst calendarNCT07283263 · readout in 90 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
106estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-23 | actual | When the study began enrolling |
| Primary completion | 2026-11-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BMS-985521
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (AEs)
measured Up to approximately Day 40
Number of participants with treatment-emergent serious adverse events (SAEs)
measured Up to approximately Day 40
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Up to approximately Day 14
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed